Diabetic retinopathy (DR) is one of the most common and serious microvascular complications of diabetes. Early diagnosis and precise intervention are key to preventing vision loss. Ace Therapeutics is a preclinical contract research organization focusing on diabetes, dedicated to providing high-quality biomarker development services to research institutions and pharmaceutical companies worldwide. We aim to provide researchers with comprehensive support from basic research to translational applications.

Why Choose Biomarker Development Services?

Traditional DR diagnosis relies on fundus imaging techniques, but these methods often only capture lesion features in the late stages of the disease, leading to missed opportunities for optimal intervention. The development of biomarkers aims to "decode" early signals of disease development at the molecular level. Whether it is tiny RNAs abnormally expressed in the blood, proteins with imbalanced levels in the tear fluid, or unique metabolites in aqueous humor, all of them may become "molecular signposts" for the prediction and diagnosis of DR. By screening and validating these biomarkers, we can not only achieve early warning of DR, but also provide precise indicators for efficacy assessment in drug development.

Fig. 1 Biomarkers for diabetic retinopathy. (Ziyan, X., 2022)

Diabetic Retinopathy Biomarker Development Services at Ace Therapeutics

Ace Therapeutics' services span the entire lifecycle of biomarker discovery, validation, and translational applications. We are committed to rigorous scientific design driven by innovative technology to ensure efficient advancement at every step of the way.

• Deep mining of biological samples: We provide diverse, high-quality diabetic animal biospecimens encompassing multiple biofluids including blood, aqueous humor, vitreous, and tears. Integrated with advanced cryopreservation and information management systems, these samples deliver premium resources for biomarker discovery.
• Multi-omics joint analysis: Integrating genomics, transcriptomics, proteomics and metabolomics technology platforms. We utilize cutting-edge equipment such as high-throughput sequencing and mass spectrometry to capture disease-related molecular features from multiple dimensions and build a comprehensive biomarker candidate library.
• Targeted validation and modeling: We use precise validation tools such as ELISA, immunohistochemistry and digital PCR, combined with machine learning and bioinformatics algorithms. We build biomarker models that predict disease onset, progression and treatment response to ensure the reliability and utility of the results.

Advantages of Our Diabetic Retinopathy Biomarker Development Services

• Multi-dimensional integration: Combining histology, imaging, and AI technologies to deliver comprehensive biomarker solutions.
• Precise intervention: Realize early intervention and precise treatment of DR through marker stratification.

Whether you're an innovative pharmaceutical company entering biomarker research or a scientific team pursuing technological breakthroughs, Ace Therapeutics develops customized solutions tailored to your requirements. From project consultation and solution design to data delivery, we help clients overcome diabetic retinopathy research challenges through highly efficient execution. Contact us to explore how we can advance your program.

Reference

1. Ziyan, X. Novel biomarkers and therapeutic approaches for diabetic retinopathy and nephropathy: Recent progress and future perspectives. Frontiers in Endocrinology. 2022, 13: 1065856.

• Diabetic Retinopathy Pathological Research Service
• In Vivo Modeling of Diabetic Retinopathy
• Diabetic Retinopathy Drug Development Service
• Diabetic Retinopathy Diagnostic Assay Development Service

• Mouse Models
• Assay Kits
• Antibodies
• Cell Lines & Lysates
• Proteins & Peptides
• Inhibitors & Activators